- Home
- VYNE vs RLMD Comparison
VYNE vs RLMD Comparison
Compare VYNE & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VYNE
- RLMD
- Stock Information
- Founded
- VYNE 2003
- RLMD 2004
- Country
- VYNE United States
- RLMD United States
- Employees
- VYNE N/A
- RLMD N/A
- Industry
- VYNE Biotechnology: Pharmaceutical Preparations
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- VYNE Health Care
- RLMD Health Care
- Exchange
- VYNE Nasdaq
- RLMD Nasdaq
- Market Cap
- VYNE 24.3M
- RLMD 20.3M
- IPO Year
- VYNE 2018
- RLMD N/A
- Fundamental
- Price
- VYNE $0.35
- RLMD $0.65
- Analyst Decision
- VYNE Buy
- RLMD Buy
- Analyst Count
- VYNE 2
- RLMD 3
- Target Price
- VYNE $8.00
- RLMD $5.00
- AVG Volume (30 Days)
- VYNE 4.1M
- RLMD 213.9K
- Earning Date
- VYNE 08-14-2025
- RLMD 08-07-2025
- Dividend Yield
- VYNE N/A
- RLMD N/A
- EPS Growth
- VYNE N/A
- RLMD N/A
- EPS
- VYNE N/A
- RLMD N/A
- Revenue
- VYNE $476,000.00
- RLMD N/A
- Revenue This Year
- VYNE $42.51
- RLMD N/A
- Revenue Next Year
- VYNE N/A
- RLMD N/A
- P/E Ratio
- VYNE N/A
- RLMD N/A
- Revenue Growth
- VYNE N/A
- RLMD N/A
- 52 Week Low
- VYNE $0.33
- RLMD $0.24
- 52 Week High
- VYNE $4.30
- RLMD $3.98
- Technical
- Relative Strength Index (RSI)
- VYNE 29.46
- RLMD 54.75
- Support Level
- VYNE $0.35
- RLMD $0.55
- Resistance Level
- VYNE $0.36
- RLMD $0.66
- Average True Range (ATR)
- VYNE 0.04
- RLMD 0.05
- MACD
- VYNE -0.02
- RLMD 0.00
- Stochastic Oscillator
- VYNE 1.79
- RLMD 82.84
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.